 Home > Active Ingredient News > Antitumor Therapy > Ther Adv Med Oncol: A retrospective study by Professor Zhong Zhong Shiming’s team found that lenvatinib + teriprizumab + hepatic arterial infusion chemotherapy (HAIC) can improve the prognosis of patients with advanced hepatocellular carcinoma

Ther Adv Med Oncol: A retrospective study by Professor Zhong Zhong Shiming’s team found that lenvatinib + teriprizumab + hepatic arterial infusion chemotherapy (HAIC) can improve the prognosis of patients with advanced hepatocellular carcinoma

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

boiler water treatment

life cycle analysis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC), but the prognosis is still unsatisfactory
.

In recent years, hepatic arterial infusion chemotherapy (HAIC) and immune checkpoint inhibitors (ICIs) have shown good therapeutic effects on advanced hepatocellular carcinoma

Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC), but the prognosis is still unsatisfactory

This is a retrospective study, including patients with lenvatinib [8mg (≤60kg) or 12mg (>60kg) qd) or lenvatinib toripalimab + HAIC [LeToHAIC group, use lenvatinib 0-1 weeks before HAIC, 0 before each HAIC cycle -1 day use toripalimab 240mg, and HAIC FOLFOX regimen
.

The progress-free survival (PFS), overall survival (OS), objective response rate (ORR) and treatment-related adverse events were compared between the two groups

From February 24, 2019 to August 2, 2019, 157 patients met the criteria for inclusion in this study: 71 patients received lenvatinib, toripalimab + HAIC triple therapy (LeToHAIC), and 86 patients received lenvatinib monotherapy Treatment

Differences in PFS and OS between the two treatment groups

In subgroup analysis, among patients without extrahepatic metastasis, the median PFS of the LeToHAIC group was longer than that of the lenvatinib monotherapy group, which was 11.
63 (95% CI, 8.
88-14.
38) and 7.
5 (95% CI, 5.
35-9.
65) months (p = 0.
004); Similarly, the median OS in the LeToHAIC group was longer than that in the lenvatinib single-drug group, which were not reached and 13.
77 (95% CI, 11.
35-16.
19) months (p = 0.
001)
.

In subgroup analysis, among patients without extrahepatic metastasis, the median PFS of the LeToHAIC group was longer than that of the lenvatinib monotherapy group, which was 11.

Differences in PFS and OS between the two treatment groups in patients without extrahepatic metastasis

In patients with extrahepatic metastases, the median PFS in the LeToHAIC group was longer than that in the lenvatinib monotherapy group, which were 6.
6 (95% CI, 0.
66-12.
55) and 4.
17 (95% CI, 2.
21-6.
13) months, respectively (p = 0.
009); Similarly, the median OS of the LeToHAIC group was prolonged compared with that of the lenvatinib monotherapy group, which were 11.
37 (95% CI, 6.
79-15.
94) and 8.
17 (95%CI, 4.
69-11.
65) months (p = 0.
09)
.

In patients with extrahepatic metastases, the median PFS in the LeToHAIC group was longer than that in the lenvatinib monotherapy group, which were 6.

Differences in PFS and OS between the two treatment groups in patients with extrahepatic metastases

Based on the RECIST criteria, the DCR and ORR of the LeToHAIC group were significantly higher than those of the lenvatinib group (90.
1% vs 72.
1%, p = 0.
005; 59.
2% vs 9.
3%, p<0.
001)
.

Based on mRECIST criteria, the DCR and ORR of the LeToHAIC group were also significantly higher than those of the lenvatinib group (90.

Based on the RECIST criteria, the DCR and ORR of the LeToHAIC group were significantly higher than those of the lenvatinib group (90.

Efficacy evaluation of different standards

The incidence of grade 3/4 treatment-related adverse events in the LeToHAIC group was higher than that in the lenvatinib group, including neutropenia (8.
5% vs 1.
2%), thrombocytopenia (5.
6% vs 0), and nausea (5.
6% vs 0)
.

In summary, studies have shown that compared with lenvatinib alone, the LeToHAIC group (Lenvatinib + toripalimab +HAIC) can improve the prognosis of patients with advanced hepatocellular carcinoma, and the toxicity is tolerable
.

Studies have shown that compared with lenvatinib alone, the LeToHAIC group (Lenvatinib + toripalimab +HAIC) can improve the prognosis of patients with advanced hepatocellular carcinoma, and the toxicity is tolerable
.
Studies have shown that compared with lenvatinib alone, the LeToHAIC group (Lenvatinib + toripalimab +HAIC) can improve the prognosis of patients with advanced hepatocellular carcinoma, and the toxicity is tolerable
.

Original source:

He MK, Liang RB, Zhao Y, Xu YJ, Chen HW, Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M.
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma.
Ther Adv Med Oncol.
2021 Mar 25;13:17588359211002720.
doi: 10.
1177/17588359211002720.
PMID: 33854567; PMCID: PMC8010824.
He MK, Liang RB, Zhao Y, Xu YJ, Chen HW , Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M.
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.